Takeda Oral Tyk2 Inhibitor, Acquired in Nimbus Deal, Raises the Bar on Psoriasis

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.